IP Library Granted Patent US 8,163,702
Granted Patent B2
US 8,163,702 · App. 12/297,699 · Granted Apr 24, 2012

Treatment of melanoma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,702
App. No.
12/297,699
Granted
Apr 24, 2012
Kind
B2
Abstract

An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.

Claims (22)

1. A method of treating or reducing melanoma or a metastasis thereof, or growth of melanoma cells or metastases thereof, in a subject in need thereof, comprising administering to the subject an effective amount of an immunomodulator compound of formula A

wherein, n is 1 or 2; R is hydrogen, C2-10 acyl, or C1-6 alkyl; and X is L-tryptophan or D-tryptophan, so as to treat or reduce said melanoma or metastasis thereof in the subject, or treat or reduce growth of said melanoma cells or metastases thereof in the subject.

2. The method of claim 1 wherein said compound is γ-D-glutamyl-L-tryptophan.

3. The method of claim 1 wherein said compound is administered at a dosage within a range of about 0.001-1000 mg.

4. The method of claim 1 wherein said compound is administered at a dosage within a range of about 0.01-100 mg.

5. The method of claim 1 wherein said compound is administered at a dosage within a range of about 0.00001-100 mg/kg subject body weight.

6. The method of claim 1 wherein said compound is administered at a dosage within a range of about 0.01-10 mg/kg subject body weight.

7. The method of claim 1 wherein said compound is γ-D-glutamyl-L-tryptophan, and is administered at a dosage within a range of about 0.001-1000 mg.

8. The method of claim 1 wherein said compound is γ-D-glutamyl-L-tryptophan and is administered at a dosage within a range of about 0.00001-100 mg/kg subject body weight.

9. The method of claim 2 wherein said treatment is for primary melanoma.

10. The method of claim 9 wherein said compound is administered at a dosage within a range of about 0.001-1000 mg.

11. The method of claim 9 wherein said compound is administered at a dosage within a range of about 0.1-100 mg.

12. The method of claim 9 wherein said compound is administered at a dosage within a range of about 0.00001-100 mg/kg subject body weight.

13. The method of claim 9 wherein said compound is administered at a dosage within a range of about 0.01-10 mg/kg subject body weight.

14. The method of claim 2 wherein said treatment is for a melanoma metastasis.

15. The method of claim 14 wherein said compound is administered at a dosage within a range of about 0.001-1000 mg.

16. The method of claim 14 wherein said compound is administered at a dosage within a range of about 0.1-100 mg.

17. The method of claim 14 wherein said compound is administered at a dosage within a range of about 0.00001-100 mg/kg subject body weight.

18. The method of claim 14 wherein said compound is administered at a dosage within a range of about 0.01-10 mg/kg subject body weight.

19. The method of claim 11 wherein said dosage is about 10 mg.

20. The method of claim 16 wherein said dosage is about 10 mg.

21. The method of claim 1 wherein said subject is a human patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: SCICLONE PHARMACEUTICALS LLC
To: SCICLONE PHARMACEUTICALS INTERNATIONAL LTD.
Reel/Frame 048990/0314 →
CHANGE OF NAME Recorded Apr 25, 2019
From: SCICLONE PHARMACEUTICALS, INC.
To: SCICLONE PHARMACEUTICALS LLC
Reel/Frame 048992/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2010
From: TUTHILL, CYNTHIA W.; RUDOLPH, ALFRED R.
To: SCICLONE PHARMACEUTICALS, INC.
Reel/Frame 024661/0608 →